
ASCO 2020: Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients…
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients…